fda compounding semaglutide update today Despite ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market The FDA Wins. The OFA

When your blood sugar has stalled too high

The boxed warning about thyroid C-cell tumors applies to all GLP-1 drugs and prohibits their use in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

GLP-1 receptor agonists stimulate insulin release only when blood sugar is elevated and suppress glucagon secretion

Retatrutide has shown promising results in clinical trials, but as it is still in the investigational phase, long-term safety is still being studied

The good news is that there are ways to manage and reduce these sulfur burps so they dont linger

Cardiovascular Health One of the most well known and studied off-label uses of GLP-1s is its use for cardiovascular health